泰格医药(300347) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 reached ¥1,939,627,566.42, representing a 7.05% increase year-over-year[2] - Net profit attributable to shareholders was ¥491,267,423.96, up 19.05% compared to the same period last year[2] - The net profit after deducting non-recurring gains and losses decreased by 3.75% to ¥404,950,398.38[2] - Total operating revenue for Q3 2023 reached ¥5,650,477,938.01, an increase of 4.52% compared to ¥5,406,018,843.59 in Q3 2022[16] - Gross profit for the period was ¥1,508,291,382.87, reflecting a gross margin of approximately 26.64%[16] - The company's net profit for Q3 2023 reached CNY 2,027,846,971.74, an increase of 14.4% compared to CNY 1,772,234,409.94 in Q3 2022[17] - Operating profit for the quarter was CNY 2,311,724,272.62, up from CNY 2,001,007,232.46 in the same period last year, reflecting a growth of 15.6%[17] - Basic and diluted earnings per share for the quarter were both CNY 2.17, compared to CNY 1.86 in the previous year, representing a growth of 16.7%[18] Assets and Liabilities - Total assets increased by 9.57% to ¥30,072,449,412.86 compared to the end of the previous year[2] - The company's total assets increased to ¥30,072,449,412.86, compared to ¥27,446,510,596.44 at the end of Q3 2022, marking a growth of 9.4%[15] - Total liabilities rose to ¥5,521,215,888.56, up from ¥4,765,479,654.95, indicating an increase of 15.87%[15] - The company's total equity reached ¥24,551,233,524.30, up from ¥22,681,030,941.49, marking a growth of 8.25%[15] Cash Flow - The company reported a net cash flow from operating activities of ¥672,644,481.56, down 18.51% year-to-date[2] - The cash inflow from operating activities was CNY 5,303,391,474.82, while cash outflow was CNY 4,630,746,993.26, resulting in a net cash inflow of CNY 672,644,481.56[19] - Net cash flow from operating activities for Q3 2023 was approximately ¥672.64 million, a decrease from ¥825.39 million in Q3 2022[20] - Net cash flow from investing activities decreased by 33.94% to -1,592,504,848.56 CNY compared to the same period last year[7] - The net cash flow from investing activities was -¥1.59 billion, improving from -¥2.41 billion year-over-year[20] - Total cash inflow from financing activities increased to approximately ¥3.06 billion, compared to ¥2.95 billion in the previous year[20] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 56,356, with the largest shareholder, Ye Xiaoping, holding 20.32% of shares, equating to 177,239,541 shares[8] - The top ten shareholders collectively hold significant stakes, with HKSCC NOMINEES LIMITED owning 14.11% (123,119,379 shares) and Hong Kong Central Clearing Limited holding 6.12% (53,420,466 shares)[8] - The company reported a total of 181,907,044 shares under lock-up agreements at the end of the reporting period, with 4,125,000 shares released during the current period[12] - The company is actively managing its shareholder structure, with notable actions taken by major shareholders, including share pledges and lock-up agreements[12] Investments and R&D - The company plans to expand its investment in joint ventures, leading to a 61.05% increase in long-term equity investments to ¥2,898,551,203.83[5] - Research and development expenses for the period were ¥195,343,150.53, compared to ¥171,055,447.09 in the previous year, indicating an increase of 14.2%[16] Other Financial Metrics - The company received government subsidies amounting to ¥10,521,363.70 year-to-date, which contributed to its financial performance[3] - The company's cash and cash equivalents amounted to 7,417,101,360.17 CNY, a decrease from 7,858,139,864.36 CNY at the beginning of the year[13] - Accounts receivable increased to 1,176,009,099.35 CNY from 1,027,789,335.66 CNY, indicating a growth in sales or credit terms extended to customers[13] - The company's cash and cash equivalents were reported at ¥11,465,404,979.73, a slight increase from ¥11,107,248,144.90 year-over-year[15] - Inventory levels increased to ¥27,238,796.09, compared to ¥22,204,440.32 in the previous year, representing a growth of 22.73%[15] Changes and Standards - The company did not undergo an audit for the Q3 report[20] - The company implemented new accounting standards starting in 2023, affecting the financial statements[20]